EGF and non-small cell lung carcinoma: As previous results published by our Institute showed, a relation between the magnitude of specific anti-EGF antibody response and the clinical outcomes of vaccinated patients has been demonstrated when using CIMAvax-EGF as switch maintenance therapy after platinum-based first-line chemotherapy in NSCLC patients.